Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Living Microbial Drugs
Date
2026-01-01
Author
Özçelik, Cemile Elif
Tunç, Nazlıcan
Şen, Senem
Şeker, Urartu Özgür Şafak
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
33
views
0
downloads
Cite This
Living microbial therapeutics have arisen as a novel category of medications that extend beyond traditional small molecules and biologics. Advancements in synthetic biology have facilitated the rational engineering of microorganisms to detect host or disease-related signals and administer therapeutic chemicals in situ. In contrast to conventional pharmaceuticals, these live biotherapeutic agents engage in dynamic interactions with both the host and its microbiota, allowing context-specific, self-regulating therapies. This review emphasizes the progression of the field from conventional probiotics to advanced, designed living therapeutics. We examine principal microbiological platforms, including bacteria, yeasts, and alternative systems such as phages and archaea, delineating their relative benefits and constraints as therapeutic hosts. Key design principles, genetic logic circuits, quorum-sensing-based regulation, and synthetic memory devices that enable microorganisms to possess context-dependent and self-adjusting therapeutic capabilities, are discussed alongside present and emerging therapeutic applications in infectious diseases, metabolic disorders, inflammatory illnesses, and cancer immunotherapy, where engineered microorganisms have demonstrated significant preclinical effectiveness and first clinical promise. Despite these advancements, obstacles remain, including biosafety, biocontainment, regulatory approval, and patient acceptability. Engineered living microbial therapeutics signify a swiftly evolving domain in medicine, set to transform treatment paradigms via intelligent, flexible, and sustainable methodologies for human health.
Subject Keywords
cell engineering
,
living microbial therapeutics
,
probiotic engineering
,
synthetic biology
,
synthetic circuit design
URI
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105036190156&origin=inward
https://hdl.handle.net/11511/119185
Journal
Chemistry - A European Journal
DOI
https://doi.org/10.1002/chem.202503523
Collections
Department of Biology, Article
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
C. E. Özçelik, N. Tunç, S. Şen, and U. Ö. Ş. Şeker, “Living Microbial Drugs,”
Chemistry - A European Journal
, pp. 0–0, 2026, Accessed: 00, 2026. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105036190156&origin=inward.